IASLC World Conference on Lung Cancer Recap
The International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC 2021) took place September 8-14, drawing over 6,000 registrants from more than 500 countries. WCLC is the only global network dedicated solely to the study of lung cancer and other thoracic malignancies, and the meeting featured many updates in NSCLC, SCLC, immunotherapy, combination therapies, disparities, clinical trials, and other diseases associated with lung cancer.
Findings and developments in the lung cancer space during early 2021
A number of interesting developments in the lung cancer research space have taken place in 2021 so far. Several new findings were introduced at the American Association for Cancer Research (AACR) and American Society for Clinical Oncology (ASCO) annual meetings as well as the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer.
Read a mid-year update with commentary from LCRF’s director of scientific programs Eugene Manley, Jr., PhD, and Kathryn Gold, MD, LCRF’s guest for our #TogetherSeparately Lung Cancer Mid-Year Update webinar.
Research developments
- SCLC molecular atlas could lead to potential new therapies
- FDA approves atezolizumab for stage II to IIIA lung cancer
- IASLC World Conference on Lung Cancer Recap
- Researchers leverage fibroblasts to enhance personalized treatment for lung cancer patients
- Lung Cancer Mutation Consortium Kicks Off Umbrella Trial
- New cancer treatments mean some patients can avoid chemotherapy
- Novel drug combinations improve progression-free survival for patients with advanced NSCLC
- FDA approves mobocertinib for EGFR exon 20 insertion+ NSCLC
- Findings and developments in the lung cancer space during the first half of 2021
Recent FDA approvals
- FDA approves atezolizumab for stage II to IIIA lung cancer
- FDA approves mobocertinib for EGFR exon 20 insertion+ NSCLC
- Findings and developments in the lung cancer space during the first half of 2021
- #TogetherSeparately Live Talk on recent FDA approvals
- Approval of Keytruda Every Six Weeks a ‘Welcome Change’ for Patients With Cancer
- FDA announcements speak to urgency of improving lung cancer treatment